Gayathri Nagaraj, MD
Medical Oncology · Loma Linda, CANPI 1346402286
Payments from drug & device makers
Across 35 payments — averaging $6653.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$180K
- AstraZeneca$41K
- Puma Biotechnology, Inc.$6K
- Merck$5K
- Novartis$839
- Caris MPI, Inc.$233
- plus $114 from 3 others
Across 1 payment — averaging $2071.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2K
What the payments were for
- Food & beverage$50390%
- Education$5710%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 6 | $179,656 |
| AstraZeneca | 2 | $41,498 |
| Puma Biotechnology, Inc. | 3 | $5,820 |
| Merck | 11 | $4,707 |
| Novartis | 9 | $839 |
| Caris MPI, Inc. | 1 | $233 |
| Daiichi Sankyo Inc. | 1 | $57 |
| Epizyme, Inc. | 1 | $45 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MI CANCER SEEK$233
How this compares
$232,866 in reported general payments places this provider in the 60th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 23 | $344,849 |
| VerzenioAbemaciclib | 16 | $232,867 |
| Everolimus | 17 | $133,657 |
| Exemestane | 32 | $5,850 |
| Letrozole | 115 | $2,850 |
| Anastrozole | 122 | $1,559 |
| Dexamethasone | 13 | $1,015 |
| Gabapentin | 31 | $644 |
| Olanzapine | 14 | $364 |
| Ondansetron Hcl | 13 | $294 |
| Omeprazole | 16 | $169 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 17 | $141 |
| Alendronate Sodium | 24 | $138 |
| Duloxetine Hcl | 15 | $137 |
| Prochlorperazine Maleate | 11 | $134 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Loma Linda
- Hamid MirshahidiLoma Linda$3.1M
- Sarmad SadeghiLos Angeles$26.1M
- Marwan FakihDuarte$24.2M
- Sumanta PalDuarte$15.9M
- Farshid DayyaniOrange$13.4M
- Daneng LiDuarte$12.4M
- Heinz-Josef LenzLos Angeles$11.6M
- Kevin KimSan Francisco$10.8M
- Anthony El-KhoueiryLos Angeles$10.5M
- Amy ChienSan Francisco$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.